Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Very short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy in older patients after PCI
2023-507545-28-00Phase 4Authorised
- Sponsor
- CHU Caen Normandie
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of prasugrel, clopidogrel, ticagrelor and lysine acetylsalicylate in acute coronary syndrome (ACS), Chronic Coronary Syndrome (CCS) and coronary arteriosclerosis (2 arms), sponsored by CHU Caen Normandie. Primary endpoint: Net clinical benefit. Planned start Mar 2026; status: authorised.
02
Drugs
prasugrelclopidogrelticagrelorlysine acetylsalicylate
03
Conditions
acute coronary syndrome (ACS)Chronic Coronary Syndrome (CCS)coronary arteriosclerosis
Beyond the preview
Go deeper on 2023-507545-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507545-28-00.